Development of Haemophilia Treatment in the Eastern Part of Germany over the Last Decade in the Kompetenznetz Hämorrhagische Diathese Ost (KHDO)

Abstract

Introduction In 2005 the Kompetenznetz Hämorrhagische Diathese Ost published epidemiologic data about patients with haemophilia A (HA) and haemophilia B (HB) in the eastern part of Germany. This study provides data about the development of treatment in these patients over the past 10 years.

Methods Data from 12 haemophilia centres in eastern Germany were retrospectively collected for the year 2015 from patients' records.

Results We evaluated 413 patients (115 children, 298 adults) with HA or HB. A total of 286 patients (69.2%) had severe haemophilia (patients with severe haemophilia, PWSH). Compared with 2005, the proportion PWSH on prophylaxis increased from 90% to 98.8% in children and from 64% to 80.2% in adults. The use of plasma-derived factor concentrates decreased from >70% to 55.3% in children and to 55.1% in adults. Mean annual factor consumption in PWSH without inhibitor was higher in 2015 compared with 2005 (children with HA: 151,489 vs. 98,894; adults with HA: 217,151 vs. 151,394; children with HB: 105,200 vs. 64,256; adults with HB: 159,185 vs. 85,295). Median annualized bleeding (annualized bleeding rate, ABR) and joint bleeding rates (annualized joint bleeding rate, AJBR) in 2015 were 2 and 0 in children and 3 and 0 in adults, respectively. In 2015 only one child (1.2%) but 101 (53.2%) adults with severe haemophilia were anti-hepatitis C virus (anti-HCV) positive. The rate of anti-HCV positive patients with active hepatitis C dropped from 63.8% to 12.9%.

Conclusions Within the last decade more patients with severe haemophilia were switched to a prophylactic regimen going along with a moderate increase in factor consumption achieving a low ABR and AJBR.

Zusammenfassung

Einleitung Im Jahr 2005 hat das Kompetenznetz Hämorrhagische Diathese Ost epidemiologische Daten über Patienten im Osten Deutschlands mit Hämophilie A (HA) und B (HB) publiziert. Diese Studie liefert Daten über die Entwicklung der Hämophiliebehandlung bei diesen Patienten in den letzten 10 Jahren.

Methoden Daten von 12 Hämophiliezentren im Osten Deutschlands aus dem Jahr 2015 wurden retrospektiv aus den Patientenakten ausgewertet.

Ergebnisse Wir untersuchten 413 Patienten (115 Kinder, 298 Erwachsene) mit HA oder HB. 286 Patienten (69,2%) hatten eine schwere Hämophilie (PMSH). Im Vergleich zu 2005 ist der Anteil der PMSH mit Prophylaxe bei den Kindern von 90% auf 98.8% und bei den Erwachsenen von 64% auf 80,2% angestiegen. Der Verbrauch von plasmatischen Faktorenkonzentraten ist von >70% auf 55,3% bei Kindern und 55,1% bei Erwachsenen gesunken. Der mittlere Faktorenverbrauch bei PMSH ohne Hemmkörper war 2015 höher als 2005 (Kinder mit HA 151.489 versus 98.894, Erwachsene mit HA 217.151 versus 151.394, Kinder mit HB 105.200 versus 64.256, Erwachsenen mit HB 159.185 versus 85.295). Die mediane jährliche Blutungsrate und Gelenkblutungsrate in 2015 war 2 bzw. 0 bei Kindern und 3 bzw. 0 bei Erwachsenen. Im Jahr 2015 war lediglich ein Kind (1,2%) aber 101 (53,2%) Erwachsene mit schwerer Hämophilie anti-HCV positiv. Der Anteil der anti-HCV-positiven Erwachsenen mit aktiver Hepatitis C fiel von 63,8% auf 12,9%.

Zusammenfassung In den letzten 10 Jahren wurden mehr Patienten auf eine prophylaktische Behandlung umgestellt. Dies geht mit einem moderaten Anstieg des Verbrauchs an Faktorenkonzentraten einher, resultiert aber in einer niedrigen Blutungsrate.

Keywords

haemophilia - epidemiologic data - factor consumption - hepatitis C

Schlüsselwörter

Hämophilie - Epidemiologie - Faktorenverbrauch - Hepatitis C

Remark: Our study includes data of 42 patients that were included in the publication by Olivieri et al, Prevalence of Obesity in Young Patients with Severe Haemophilia and Its Potential Impact on Factor VIII Consumption in Germany. Hamostaseologie 2019. doi10.1055/s-0039-1677874.

• References

• 1 Srivastava A, Brewer AK, Mauser-Bunschoten EP. , et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19 (01) e1-e47
• 2 den Uijl I, Biesma D, Grobbee D, Fischer K. Outcome in moderate haemophilia. Blood Transfus 2014; 12 (Suppl. 01) s330-s336
• 3 Manco-Johnson MJ, Abshire TC, Shapiro AD. , et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357 (06) 535-544
• 4 Tagliaferri A, Feola G, Molinari AC. , et al; POTTER Study Group. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study. Thromb Haemost 2015; 114 (01) 35-45
• 5 Manco-Johnson MJ, Lundin B, Funk S. , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. J Thromb Haemost 2017; 15 (11) 2115-2124
• 6 Nijdam A, Foppen W, van der Schouw YT, Mauser-Bunschoten EP, Schutgens REG, Fischer K. Long-term effects of joint bleeding before starting prophylaxis in severe haemophilia. Haemophilia 2016; 22 (06) 852-858
• 7 Hesse J. deutsches-haemophilieregister-dhr-patientenzahlen. Available at: https://www.pei.de/SharedDocs/Downloads/blut/dhr-deutsches-haemophilieregister/deutsches-haemophilieregister-dhr-patientenzahlen.pdf?__blob=publicationFile&v=54 . Accessed January 16, 2019
• 8 Scholz U, Syrbe G, Koscielny J, Klamroth R. ; Kompetenznetzwerk Hämorrhagische Diathesen Ost (KHDO). Patienten mit Hämophilie A, B oder von-Willebrand-Syndrom Typ 3. Systematische Erfassung im Osten Deutschlands. Hamostaseologie 2008; 28 (03) 150-154
• 9 Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. ; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12 (11) 1935-1939
• 10 World Health Organization. Obesity and overweight. Available at: http://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight . Updated February 16, 2018 . Accessed November 14, 2018
• 11 Kromeyer-Hauschild K, Wabitsch M, Kunze D. , et al. Perzentile für den Body-mass-Index für das Kindes- und Jugendalter unter Heranziehung verschiedener deutscher Stichproben. Monatsschr Kinderheilkd 2001; 149 (08) 807-818
• 12 Moss A, Wabitsch M, Kromeyer-Hauschild K, Reinehr T, Kurth B-M. Prävalenz von Ubergewicht und Adipositas bei deutschen Einschulkindern. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2007; 50 (11) 1424-1431
• 13 Olivieri M, Königs C, Heller C. , et al. Prevalence of obesity in young patients with severe haemophilia and its potential impact on factor VIII consumption in Germany. Hamostaseologie 2019 (e-pub ahead of print) Doi: 10.1055/s-0039-1677874
• 14 Chen CX, Baker JR, Nichol MB. Economic burden of illness among persons with hemophilia B from HUGS Vb: examining the association of severity and treatment regimens with costs and annual bleed rates. Value Health 2017; 20 (08) 1074-1082
• 15 Collins PW. Personalized prophylaxis. Haemophilia 2012; 18 (Suppl. 04) 131-135
• 16 Jiménez-Yuste V, Auerswald G, Benson G. , et al. Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. Blood Transfus 2014; 12 (03) 314-319
• 17 Herbert RD, Broderick CR, Barnes C, Billot L, Zhou A, Latimer J. Optimization of prophylaxis for hemophilia A. PLoS One 2018; 13 (02) e0192783
• 18 Iorio A, Edginton AN, Blanchette V. , et al. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: rationale and general considerations. Res Pract Thromb Haemost 2018; 2 (03) 535-548
• 19 Tischer B, Marino R, Napolitano M. Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice. Patient Prefer Adherence 2018; 12: 431-441
• 20 Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998; 19 (02) 139-148
• 21 Bacon CL, Singleton E, Brady B. , et al. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®). Haemophilia 2011; 17 (03) 407-411
• 22 Santagostino E, Auerswald G, Benson G. , et al. Switching treatments in haemophilia: is there a risk of inhibitor development?. Eur J Haematol 2015; 94 (04) 284-289
• 23 Peyvandi F, Mannucci PM, Garagiola I. , et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 2016; 374 (21) 2054-2064
• 24 Kahan S, Cuker A, Kushner RF. , et al. Prevalence and impact of obesity in people with haemophilia: review of literature and expert discussion around implementing weight management guidelines. Haemophilia 2017; 23 (06) 812-820
• 25 Henrard S, Speybroeck N, Hermans C. Body weight and fat mass index as strong predictors of factor VIII in vivo recovery in adults with hemophilia A. J Thromb Haemost 2011; 9 (09) 1784-1790
• 26 Blanchette VS, Shapiro AD, Liesner RJ. , et al; rAHF-PFM Clinical Study Group. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6 (08) 1319-1326
• 27 Tuinenburg A, Biere-Rafi S, Peters M. , et al. Obesity in haemophilia patients: effect on bleeding frequency, clotting factor concentrate usage, and haemostatic and fibrinolytic parameters. Haemophilia 2013; 19 (05) 744-752